GlobeNewswire Inc.··Eyepoint, Inc.EyePoint Pharmaceuticals Names Veteran Ophthalmology Executive Campbell as CCO
EyePoint Pharmaceuticals appoints Michael Campbell as Chief Commercial Officer. The ophthalmology veteran brings 30+ years of experience to lead commercial strategy for DURAVYU ahead of 2026 clinical data.
EYPTPhase 3 clinical trialophthalmology